=Akcea Therapeutics (AKCA) reported earnings on Mon 26 Feb 2018 (a/h)

Akcea Therapeutics misses by $0.20, beats on revs 

• Reports Q4 (Dec) loss of $0.35 per share, $0.20 worse than the two analyst estimate of ($0.15). Revenue totaled $18.04 mln, up 100% y/y
  • Co expects approval and launch of volanesorsen in mid-2018 in patients with FCS in US, EU and Canada.
  • Co will report top line results in the second half of 2018 from a Phase 2b trial of AKCEA-APO(a)-LRx in patients with high lipoprotein(a).
  • Co expects to report top line results in 2018 from an exploratory Phase 2 study of AKCEA-ANGPTL3-LRx in patients with rare hyperlipidemias.